Altimmune, Inc.
Altimmune, Inc.
Your view on ALT
Overview
What the company does, where it operates, and who runs it.
About Altimmune, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Vipin K. Garg
- Headquarters
- 910 Clopper Road, Gaithersburg, MD, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Vipin K. Garg
- Headquarters
- 910 Clopper Road, Gaithersburg, MD, US
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases.
The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis.
It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus.
The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for Altimmune, Inc. from FRC's valuation model, read against the market price. ALT last traded at $1.56; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Altimmune, Inc.. Starting points for Altimmune, Inc.: EPS -$0.51, beta 0.18 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Altimmune, Inc.. Altimmune, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Altimmune, Inc.. Trailing twelve-month EPS for Altimmune, Inc. stands at -$0.51. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$10.83
average of 3 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy4
- Hold0
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | -$0.17 | -$0.16 | -$0.61 | -$0.67 |
| Low estimate | -$0.21 | -$0.17 | -$0.68 | -$0.90 |
| High estimate | -$0.15 | -$0.14 | -$0.56 | -$0.55 |
| No. of analysts | 4 | 3 | 6 | 7 |
| Year-ago EPS | -$0.27 | -$0.18 | -$1.00 | — |
| Growth | +37.1% | +9.1% | +38.9% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $1750.00 | $18.49M | $1875.00 | $25.73M |
| Low estimate | $1750.00 | $18.49M | $1875.00 | $25.73M |
| High estimate | $1750.00 | $18.49M | $1875.00 | $25.73M |
| No. of analysts | 9 | 9 | 6 | 6 |
| Year-ago revenue | $26000.00 | $0.00 | $41000.00 | — |
| Growth | -93.3% | — | -95.4% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider, Benzinga; as of Nov 18, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Altimmune, Inc.. Altimmune, Inc. has reported as a listed company since 2017. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- ABUSArbutus Biopharma CorporationBiotechnology$619M
- ALGSAligos Therapeutics, Inc.Biotechnology$10M
- ASMBAssembly Biosciences, Inc.Biotechnology$436M
- BMEABiomea Fusion, Inc.Biotechnology$38M
- ENTAEnanta Pharmaceuticals, Inc.Biotechnology$311M
- GPCRStructure Therapeutics Inc.Biotechnology$1.1B
- INDPIndaptus Therapeutics, Inc.Biotechnology$391M
- IVAInventiva S.A.Biotechnology$173M
More Biotechnology companies
- PSYBFPsyBio Therapeutics Corp.OTC$1,275
- PTCHFPureTech Health plcOTC$410M
- PTCTPTC Therapeutics, Inc.NASDAQ$5.1B
- PTGXProtagonist Therapeutics, Inc.NASDAQ$8.1B
- PTHSPelthos Therapeutics Inc.AMEX$28M
- PTIXProtagenic Therapeutics, Inc.NASDAQ$470,654
- PTNPalatin Technologies, Inc.NASDAQ$11M
- PTX.AXPrescient Therapeutics LimitedASX
- PULMPulmatrix, Inc.NASDAQ$5M
- PVCTProvectus Biopharmaceuticals, Inc.OTC$19M
- PVLAPalvella Therapeutics, Inc.NASDAQ$2.1B
- PXMDPaxMedica, Inc. Common StockOTC$37,879
ETFs holding Altimmune, Inc.
% of the fund
- IWMiShares Russell 2000 ETF$76.6B in assets0.01%
- XBIState Street SPDR S&P Biotech ETF$10.0B in assets0.07%
- VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
- VXFVanguard Extended Market ETF$30.2B in assets0.00%
- BBCVirtus LifeSci Biotech Clinical Trials ETF$32M in assets0.49%
- SBIOALPS Medical Breakthroughs ETF$187M in assets0.20%
- IWCiShares Micro-Cap ETF$1.2B in assets0.08%
- VTWVVanguard Russell 2000 Value ETF$1.3B in assets0.03%
Largest holders first, then the funds most concentrated in ALT.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Altimmune, Inc., and how their positions are changing. At a $303.6M market value, institutional positions materially move Altimmune, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Altimmune, Inc. executives and directors. Shares of Altimmune, Inc. have traded between $2.90 and $10.88 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Altimmune, Inc.. Coverage tracks Altimmune, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Altimmune, Inc.